iBio, Inc. Files 8-K for Operations and Financials

TL;DR

IBIO filed an 8-K for financial and operational updates, no major news.

AI Summary

On May 13, 2024, iBio, Inc. filed an 8-K report to disclose information regarding its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational updates beyond the reporting of these items.

Why It Matters

This filing indicates that iBio, Inc. is providing updates on its financial performance and operational status to the SEC, which is standard for public companies.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for financial reporting and does not contain any new material information that would inherently increase risk.

Key Players & Entities

• iBio, Inc. (company) — Registrant
• May 13, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 001-35023 (company_id) — SEC File Number
• 26-2797813 (company_id) — IRS Employer Identification No.
• 8800 HSC Parkway Bryan, Texas 77807 (address) — Principal executive offices
• ( 979 ) 446-0027 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share IBIO NYSE Ameri

Filing Documents

• ibio-20240513x8k.htm (8-K) — 33KB
• ibio-20240513xex99d1.htm (EX-99.1) — 17KB
• 0001420720-24-000018.txt ( ) — 175KB
• ibio-20240513.xsd (EX-101.SCH) — 4KB
• ibio-20240513_def.xml (EX-101.DEF) — 3KB
• ibio-20240513_lab.xml (EX-101.LAB) — 14KB
• ibio-20240513_pre.xml (EX-101.PRE) — 10KB
• ibio-20240513x8k_htm.xml (XML) — 5KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On May 13, 2024, iBio, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. The following exhibit is furnished with this Current Report on Form 8-K. Exhibit Number Exhibit Description 99.1 Press Release, issued by iBio, Inc. dated May 13, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IBIO, INC. Date: March 13, 2024 By: /s/ Marc A. Banjak Name: Marc A. Banjak Title: General Counsel and Corporate Secretary